Advanced therapy medicinal products - a new era of medicine


Michael Eder

December 20, 2021

Table of contents


Advanced therapy medicinal products (ATMPs) are medicines for human use that are based on genes, tissues or cells. Accordingly, they can be classified into three main types, namely 

  • gene therapy
  • tissue engineered- and 
  • somatic-cell therapy medicines. 

According to Pink Sheet, which provides global policy and regulatory coverage, there are currently 14 approved types of cell and gene therapy available globally.​ However, there are a number of challenges that still need to be met in order to ensure unrestricted patient access to ATMPs in Europe, the US and beyond.1 

ATMPs: An overview of regulated products

The term ATMP is an European Union specific classification. It ensures that products of this category are regulated as medicines according to the EMA's (european medicines agency) Advanced Therapy Medicinal Products (ATMPs) regulatory framework (EC/1394/2007). All ATMPs are autologous. They are produced through biological processes, with the biologically sourced active pharmaceutical ingredient either being a recombinant nucleic acid or cells. There are three subdivisions of ATMPs, which we will investigate more closely in the following paragraphs.

Gene therapy medicines

As a subcategory of cell and gene therapies, gene therapy products contain genes that lead to a therapeutic, prophylactic or diagnostic effect. They are used to treating cancer and different genetic disorders. Gene therapy products work on the concept of inserting recombinant or genetically modified genes into the body and are produced within a complex manufacturing process.

Somatic-cell therapy medicines

Somatic cell therapy medicinal products contain cells or human tissues that have been manipulated in the lab to change their biological characteristics. They can be used to cure, diagnose or prevent diseases such as cancer. One such therapy is the CAR T-cell therapy, an ex vivo cell therapy. It has proven to be a promising clinical development in the treatment of patients suffering from certain types of lymphoma and leukemia.

Tissue-engineered medicines

As a subcategory of ATMPs, tissue-engineered medicines contain tissue or cells that have been modified with the aim to repair, regenerate or replace human tissue. By enabling tissue regeneration where natural regeneration is impossible, tissue engineering in ATMPs are a promising approach in cases of organ failure or major tissue damage.

ATMPs overview for cell & gene therapies

Availability & Costs of ATMPs

As of early 2021, there are 20 cell and gene therapies approved by the FDA available in the US, with a large number of ATMPs being investigated in preclinical and clinical trials.

The number of available advanced therapy medicinal products is constantly increasing. However, they are still an exclusive commodity, with patient access being limited. And so, while these innovative medicines may promise a cure for the previously incurable, they still have to overcome a number of hurdles before becoming widely available. 

One of the major challenges is related to manufacturing: So far, only a precious few manufacturers of EMA- and FDA-approved ATMPs have managed to successfully transition from small-scale clinical development to a sustainable commercial development of ATMPs. This can, not least, be attributed to the requirements of autologous therapies, which differ greatly from traditional public health products.

Challenges in ATMP manufacturing

Cell and gene therapies as well as tissue-engineered products usually require small volumes of autologous matter. Along with the need for substantial manipulation, the inability to scale is driving costs in the field of regenerative medicine. This is why manufacturers are looking to adopt flexible systems and solutions that are capable of adapting quickly, both to changing demands and new technologies.

Apart from flexibility, safety and speed are key when it comes to of cell and gene therapy medicinal products or tissue-engineered products. 

  • Safety: Regenerative medicine requires an environment designed to manipulate human cells and genetic material. The consequences of cross-contamination are dire, which is why every last aspect has to be designed according to a robust risk management strategy in compliance with all the applicable standards and regulatory considerations.
  • Speed: With patients' lives depending on speedy development and delivery of stem cell- or other autologous therapies, fast delivery is of the essence. It can only be achieved by ensuring that a functioning and reliable supply chain is in place. Without it, the healthcare system will fail to address even basic medical needs.

By implementing solutions based on single-use technology, all three of these pain points - flexibility, safety, and speed - can be addressed. In addition, single-use systems can be integrated in existing platforms, while offering the added benefits of being scalable. This makes them an ideal solution for any lab developing ATMPs and other innovative medicines as well as manufacturers in the field of regenerative medicine. 

Good news: There are already solutions for ATMPs supply chains

The aim to find solutions that address bottlenecks in pharmacology is a driving force at Single Use Support. The company is replacing established systems with single-use technologies that are compliant with any regulatory considerations (EMA and FDA), thus 

  • providing innovative end-to-end solutions for small and large batch sizes and
  • ensuring safe and fast drug substance logistics

Being composed of single-use components, such comprehensive supply chain solutions can be adapted to a wide range of needs and requirements. They offer the option of being scaled either up or down at any stage. This is an important feature when it comes to cell and gene therapies, as well as other individual therapies that generally only require a small volume of autologous matter.

Other benefits include, but are not limited to, reduced lead times, optimized warehousing costs, and - most importantly - a significantly higher degree of flexibility and agility throughout the entire development and manufacturing processes including logistics.

App Note: "Bestcellers": Controlled Filling & Freezing of Cells

"Bestcellers": Controlled Filling & Freezing of Cells Advanced Fluid Management for Cell Culture, Freezing, Cell Banking and Cell Therapy

App Note: The Chilled Future of RNA Therapeutics Filling & Freezing Applications

Traditional and rigid manufacturing processes are not for Advanced Therapies. Since novel therapies push limits in biotechnology, life science needs to keep up with adequate process solutions around commercialization of these specific therapies. Yes, SARS-CoV-2 has largely boosted the acceptance of mRNA in vaccines. And RNA vaccines and therapeutics won’t stop to fulfil unmet medical needs. But biotechs and biopharma companies continuously advancing novel treatments while solution provider drive process optimization to increase efficiency. With different product characteristics come different challenges and risks for fluid management. Therefore, modular, and flexible technologies facilitate ATMPs (Advanced Therapy Medicinal Products) manufacturing. Adjustability of process solutions to different requirements and scenarios will satisfy the needs of biomanufacturing and biotechnology companies as well as CMOs and CDMOs along the journey from drug development to commercialization.

Conclusion: The further development of Advanced therapy medicinal products

With their range of cell and gene therapies, ATMPs offer groundbreaking new opportunities for the treatment of various diseases and injuries. They provide innovative medicines that are addressing an unmet need in the aim to cure rare diseases.

This being said, so far the costs for treatment with any ATMP prove to be a challenge when it comes to patient access, as they are likely to exceed the theoretical acquisition cost. Single Use Support provides valuable solutions for CGT processes.

  1. PinkSheet Informa Pharma Intelligence, Amanda Micklus,, Published 04.01.2021

Michael Eder

Senior Marketing Manager

Michael Eder, MA, is Senior Marketing Manager at Single Use Support. He is expert in pharma and health communication with his 8+ years experience in pharma. After completing his master's degree in International Healthcare Management at MCI The Entrepreneurial school in Innsbruck, he has gained experience in the pharmaceutical field. Michael creates articles about Freeze Thaw applications and Platform solutions from Single Use Support and is the author of current news with Single Use Support worldwide. 

More from Michael Eder


The development process of biosimilars

The development process of biosimilars slightly differs from the one of their reference biologics. In this article, we will discuss each phase in detail.


Michael Eder

May 13, 2024


Biomanufacturing: Process, steps and challenges in manufacturing biologics

As biologics have become a central pillar in today’s healthcare sector, their manufacturing process increasingly draws attention. In this article, we will discuss the process step by step, including challenges and possible ways to overcome them.


Michael Eder

May 13, 2024

Read more about Cell & Gene Therapy

Cell & Gene Therapy

Study: Optimizing Cell Viability During CHO Cell Freezing

In a recent study, freezing protocols were tested with the RoSS.LN2F controlled liquid nitrogen freezer to find the optimal freezing rate for CHO-K1 cells in order to achieve maximum cell viability. 

Alexander Fuchs | Single Use Support

Alexander Fuchs

February 16, 2024

Cell & Gene Therapy

Regulations for Cryoprotectants in ATMP Cryopreservation

Adequate quality control samples retained before cell therapy treatment are a crucial component of effective regulation and need to represent the conditions and history in the cryobag. A deep dive into GMP Annex 1 on ATMP Cryopreservation.

Khalil Essani - Single Use Support

Khalil Essani

February 7, 2024

Cell & Gene Therapy

Stressing Cells: The Role of Cryoprotectants in ATMP Cryopreservation

The objective of an optimal cryopreservation strategy is to deactivate (put on hold) degenerative cellular pathways and preserve proliferative potential by reducing the temperature below –130°C. To reduce the effects of ice crystal and osmotic injuries, cryopreservation protocols usually incorporate cryoprotective agents (CPAs).

Khalil Essani - Single Use Support

Khalil Essani

February 8, 2024

Cell & Gene Therapy

Optimizing pDNA production using advanced single-use technologies

Considering the widespread need for efficient pDNA production, the industry is seeking to improve the current manufacturing process. In this article, we will discover how single-use technologies can contribute to pDNA manufacturing optimizations.

Khalil Essani - Single Use Support

Khalil Essani

November 10, 2023